Form 4: Immunome Inc. Executive Bruce Turner Acquires 110,000 Stock Options

Bruce Turner, Chief Strategy Officer of Immunome Inc., reports the acquisition of 110,000 stock options.

Summary

• On August 9, 2024, Bruce Turner, the Chief Strategy Officer of Immunome Inc., acquired 110,000 stock options.
• The exercise price of these options is $12.92.
• 25% of the shares subject to the options vest on August 9, 2025, and the remaining shares vest monthly over the following three years.
• The options expire on August 8, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition. The vesting schedule and exercise price are typical. The acquisition of options by an executive is generally viewed as a positive sign, but without additional context, it's difficult to assess the overall impact.

Positives

• The acquisition of stock options by a key executive could signal confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This allows investors to track the buying and selling activity of executives and directors, which can provide insights into their perspectives on the company's valuation and future prospects.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedule described (25% after one year, then monthly) is a fairly standard vesting arrangement.
• Comparable companies such as Regeneron, Amgen, and Gilead also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The acquisition of stock options by a key executive could positively influence shareholder sentiment.

Key Dates